Employees: 11 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2007-07-01 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MARSEILLE (13008), Bouches-du-Rhone
PHARMACIE PRADO SAINT GINIEZ : revenue, balance sheet and financial ratios
PHARMACIE PRADO SAINT GINIEZ is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MARSEILLE (13008),
this company of category PME
shows in 2025 a revenue of 3.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE PRADO SAINT GINIEZ (SIREN 497707224)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue
3 229 468 €
3 150 749 €
2 765 015 €
2 560 899 €
1 968 724 €
1 744 278 €
1 812 036 €
1 742 773 €
1 601 511 €
1 604 391 €
1 638 458 €
Net income
76 167 €
31 135 €
13 568 €
36 119 €
10 456 €
38 553 €
102 901 €
120 492 €
117 331 €
129 098 €
97 023 €
EBITDA
129 295 €
159 424 €
54 786 €
111 811 €
49 518 €
74 610 €
147 863 €
161 038 €
163 409 €
136 109 €
184 916 €
Net margin
2.4%
1.0%
0.5%
1.4%
0.5%
2.2%
5.7%
6.9%
7.3%
8.0%
5.9%
Revenue and income statement
In 2025, PHARMACIE PRADO SAINT GINIEZ achieves revenue of 3.2 M€. Over the period 2015-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +7.0%. Vs 2024: +2%. After deducting consumption (2.2 M€), gross margin stands at 985 k€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 129 k€, representing 4.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 76 k€, i.e. 2.4% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2025)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
3 229 468 €
Gross margin (2025)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
984 654 €
EBITDA (2025)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
129 295 €
EBIT (2025)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
105 064 €
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
76 167 €
EBITDA margin (2025)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
4.0%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 8%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.8 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 3.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
8.101%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
58.343%
Cash flow / Revenue (2025)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
3.106%
Repayment capacity (2025)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
0.825
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE PRADO SAINT GINIEZ
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
172.206
88.203
66.58
44.567
32.148
35.296
29.575
23.418
17.897
8.437
8.101
Financial autonomy
24.998
37.103
48.44
56.823
59.384
58.641
55.136
55.52
55.262
58.476
58.343
Repayment capacity
3.386
4.864
2.859
2.307
2.225
5.7
7.599
3.201
4.353
0.568
0.825
Cash flow / Revenue
8.832%
5.328%
7.741%
7.422%
6.505%
3.033%
1.701%
2.479%
1.359%
4.461%
3.106%
Sector positioning
Debt ratio
8.12025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of PHARMACIE PRADO SAINT GINIEZ (8.10) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
58.34%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE PRADO SAINT GINIEZ (58.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
0.82 years2025
2023
2024
2025
Q1: 0.51 years
Med: 2.46 years
Q3: 6.17 years
Good-26 pts over 3 years
In 2025, the repayment capacity of PHARMACIE PRADO SAINT GINIEZ (0.82) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 117.22. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 3.9x. Financial charges are adequately covered by operations.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
117.221
Interest coverage (2025)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
3.876
Liquidity indicators evolution PHARMACIE PRADO SAINT GINIEZ
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
88.632
111.029
133.618
160.471
164.402
185.854
128.834
126.507
115.832
105.648
117.221
Interest coverage
7.421
8.65
6.527
5.752
5.784
11.241
20.716
14.989
20.179
6.456
3.876
Sector positioning
Liquidity ratio
117.222025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch
In 2025, the liquidity ratio of PHARMACIE PRADO SAINT GINIEZ (117.22) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
3.88x2025
2023
2024
2025
Q1: 0.0x
Med: 1.91x
Q3: 5.98x
Good-13 pts over 3 years
In 2025, the interest coverage of PHARMACIE PRADO SAINT GINIEZ (3.9x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 15 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 61 days. Excellent situation: suppliers finance 46 days of the operating cycle (retail model). Inventory turnover is 34 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 41 days of revenue, i.e. 366 k€ to permanently finance. Over 2015-2025, WCR increased by +437%, requiring additional financing.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
366 157 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
15 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
61 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
34 j
WCR in days of revenue (2025)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
41 j
WCR and payment terms evolution PHARMACIE PRADO SAINT GINIEZ
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
68 127 €
107 831 €
124 277 €
184 804 €
194 341 €
174 480 €
219 316 €
449 643 €
480 698 €
348 819 €
366 157 €
Inventory turnover (days)
18
17
18
31
32
35
45
44
46
38
34
Customer payment term (days)
6
15
12
9
7
8
4
9
10
10
15
Supplier payment term (days)
69
89
53
45
60
55
74
70
74
59
61
Positioning of PHARMACIE PRADO SAINT GINIEZ in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE PRADO SAINT GINIEZ is estimated at
1 329 005 €
(range 849 037€ - 1 784 421€).
With an EBITDA of 129 295€, the sector multiple of 7.7x is applied.
The price/revenue ratio is 0.61x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
849k€1329k€1784k€
1 329 005 €Range: 849 037€ - 1 784 421€
NAF 5 année 2025
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
129 295 €×7.7x
Estimation998 197 €
503 386€ - 1 453 166€
Revenue Multiple30%
3 229 468 €×0.61x
Estimation1 959 744 €
1 443 776€ - 2 260 438€
Net Income Multiple20%
76 167 €×15.9x
Estimation1 209 922 €
821 059€ - 1 898 534€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE PRADO SAINT GINIEZ with other companies in the same sector:
Frequently asked questions about PHARMACIE PRADO SAINT GINIEZ
What is the revenue of PHARMACIE PRADO SAINT GINIEZ ?
The revenue of PHARMACIE PRADO SAINT GINIEZ in 2025 is 3.2 M€.
Is PHARMACIE PRADO SAINT GINIEZ profitable?
Yes, PHARMACIE PRADO SAINT GINIEZ generated a net profit of 76 k€ in 2025.
Where is the headquarters of PHARMACIE PRADO SAINT GINIEZ ?
The headquarters of PHARMACIE PRADO SAINT GINIEZ is located in MARSEILLE (13008), in the department Bouches-du-Rhone.
Where to find the tax return of PHARMACIE PRADO SAINT GINIEZ ?
The tax return of PHARMACIE PRADO SAINT GINIEZ is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE PRADO SAINT GINIEZ operate?
PHARMACIE PRADO SAINT GINIEZ operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart